In the landmark MONARCH-E trial, high-risk patients with ER+/Her2- breast cancer were randomized to receive either adjuvant endocrine therapy alone or adjuvant endocrine therapy with the CDK 4/6 inhibitor abemaciclib. Here, ERBB2 is linked to breast carcinoma.